loading
Schlusskurs vom Vortag:
$2.09
Offen:
$2.08
24-Stunden-Volumen:
94,372
Relative Volume:
0.06
Marktkapitalisierung:
$28.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.16M
KGV:
-6.1765
EPS:
-0.34
Netto-Cashflow:
$-39.49M
1W Leistung:
+1.94%
1M Leistung:
+3.96%
6M Leistung:
-27.34%
1J Leistung:
-35.19%
1-Tages-Spanne:
Value
$2.08
$2.14
1-Wochen-Bereich:
Value
$2.03
$2.1762
52-Wochen-Spanne:
Value
$1.83
$9.19

Dare Bioscience Inc Stock (DARE) Company Profile

Name
Firmenname
Dare Bioscience Inc
Name
Telefon
858-926-7655
Name
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
23
Name
Twitter
@DareBioscience
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
DARE's Discussions on Twitter

Vergleichen Sie DARE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DARE
Dare Bioscience Inc
2.10 28.17M 0 -30.16M -39.49M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten

pulisher
Sep 30, 2025

Daré Bioscience enters into $15M stock purchase agreement - MSN

Sep 30, 2025
pulisher
Sep 29, 2025

Dare Bioscience risks Nasdaq delisting over market value - MSN

Sep 29, 2025
pulisher
Sep 24, 2025

DARE Secures Gates Foundation Funding for Preeclampsia Projects - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Daré Bioscience, Inc. Secures $499,000 Grant from Gates Foundation to Address Preeclampsia in Women's Health - Quiver Quantitative

Sep 24, 2025
pulisher
Sep 24, 2025

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewswire

Sep 24, 2025
pulisher
Sep 24, 2025

76,000 Maternal Deaths Annually: Daré Bioscience Receives Gates Grant to Combat Preeclampsia Crisis - Stock Titan

Sep 24, 2025
pulisher
Sep 21, 2025

Dare Bioscience (NASDAQ:DARE) Shares Pass Below 200 Day Moving Average – What’s Next? - Defense World

Sep 21, 2025
pulisher
Sep 17, 2025

Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN

Sep 17, 2025
pulisher
Sep 14, 2025

What’s the recovery path for long term holders of Daré Bioscience Inc.Inflation Watch & Low Drawdown Investment Ideas - newser.com

Sep 14, 2025
pulisher
Sep 12, 2025

Using Python tools to backtest Daré Bioscience Inc. strategies2025 Price Action Summary & Comprehensive Market Scan Insights - Newser

Sep 12, 2025
pulisher
Sep 04, 2025

Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView

Sep 04, 2025
pulisher
Sep 04, 2025

Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com Canada

Sep 04, 2025
pulisher
Sep 04, 2025

Dare Bioscience (DARE) Upgraded to Buy by Maxim Group | DARE Sto - GuruFocus

Sep 04, 2025
pulisher
Sep 04, 2025

Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener

Sep 04, 2025
pulisher
Sep 04, 2025

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Sep 04, 2025
pulisher
Sep 03, 2025

Daré Bioscience Engages Market with New Presentation - TipRanks

Sep 03, 2025
pulisher
Aug 28, 2025

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN

Aug 28, 2025
pulisher
Aug 23, 2025

Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser

Aug 23, 2025
pulisher
Aug 19, 2025

Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 19, 2025

Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada

Aug 18, 2025
pulisher
Aug 18, 2025

Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks

Aug 18, 2025
pulisher
Aug 15, 2025

Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Daré Bioscience Announces Q2 2025 Financial Results - TipRanks

Aug 15, 2025
pulisher
Aug 14, 2025

Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan

Aug 14, 2025
pulisher
Aug 08, 2025

Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - The Manila Times

Aug 07, 2025
pulisher
Aug 07, 2025

Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan

Aug 07, 2025
pulisher
Jul 30, 2025

Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times

Jul 29, 2025

Finanzdaten der Dare Bioscience Inc-Aktie (DARE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Kapitalisierung:     |  Volumen (24h):